<DOC>
	<DOCNO>NCT01992341</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics paclitaxel give alone combination AMG 386 determine whether AMG 386 alters pharmacokinetics paclitaxel</brief_summary>
	<brief_title>AMG 386 Drug-Drug Interaction Study With Paclitaxel</brief_title>
	<detailed_description>Eligible subject enrol study begin receive paclitaxel three week / one week schedule study day 1 weekly AMG 386 begin study day 8 . The pharmacokinetic portion study occur first two study cycle intensive PK collection study week 1 , 6 8 . Once pharmacokinetic assessment period complete , continue combination therapy AMG 386 paclitaxel single-agent AMG 386 administer investigator 's discretion progression , unacceptable toxicity develop , study withdrawal .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Men woman ≥ 18 year age Have pathologically document , definitely diagnose , advance solid tumor refractory standard treatment , curative therapy available Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Normal clinically acceptable ECG ( 12 lead reporting PR , QRS , QTc ) Subjects gastric cancer malignancy purely squamous cell histology Known history primary central nervous system ( CNS ) tumor CNS metastases Myocardial infarction within 1 year study day 1 , unstable uncontrolled disease/condition relate affect cardiac function History stroke , arterial venous thrombosis , pulmonary embolism within 1 year study day 1 A baseline ECG QTc interval &gt; 450 msec Active grade 2 great peripheral vascular disease History pulmonary hemorrhage gross hemoptysis within 6 month study day 1 Nonhealing wound , ulcer ( include gastrointestinal ) fracture Known positive test human immunodeficiency virus infection , active hepatitis B hepatitis C infection Major surgery within 1 month study day 1 Concurrent antitumor treatment within 4 week ( 6 week nitrosoureas mitomycin ) study day 1 Unable tolerate IV administration repeat blood withdrawal Hypersensitivity paclitaxel drug use vehicle cremophor Known sensitivity mammalianderived product , bacteriallyproduced protein , product administer dose Chronic neuropathy grade ≥ 1 Concurrent prior treatment 2C8 3A4 substrate Enrolled yet complete least 30 day ( prior study day 1 ) since end investigational device drug , currently receive investigational treatment . Men woman reproductive potential , unwilling practice highly effective method birth control duration study additional 6 month last dose AMG 386 Women lactating/breastfeeding Women positive pregnancy test Women plan become pregnant duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>sarcoma</keyword>
	<keyword>carcinoma</keyword>
</DOC>